
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Pheochromocytoma laboratory findings
Introduction
Overview
Overview
Laboratory findings consistent with the diagnosis of pheochromocytoma include elevated 24-hour urinary fractionated catecholamines and metanephrines for low-risk patients and plasma fractionated metanephrines for high-risk patients.
Laboratory Findings
Laboratory Findings
An elevated concentration of the following is diagnostic of pheochromocytoma.
- Elevated 24-hour urine fractionated metanephrines and catecholamines. The cutoff values are: [1]
- Normetanephrine >900Â mcg/24Â hours
- Metanephrine >400Â mcg/24Â hours
- Norepinephrine >170Â mcg/24Â hours
- Epinephrine >35Â mcg/24Â hours
- Dopamine >700Â mcg/24Â hours
- Elevated plasma fractionated metanephrines. The cutoff values are:
- Elevated urinary vanillyl mandelic acid [4] [2]
The following drugs interfere with urinary catecholamines metabolism and shoudl be discontinued two weeks before any hormonal assessments: [5]
- Tricyclic antidepressants (TCAs)
- Levodopa
- Antipsychotics
- Ethanol
- Acetaminophen
- Phenoxybenzamine [6]
Patients with spells of elevated blood pressure (sudden onset of a symptom or symptoms) can be negative in-between spells and should be tested directly after the attacks.[7]
References
References
- ↑ Sawka AM, Jaeschke R, Singh RJ, Young WF (2003). “A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines”. J Clin Endocrinol Metab. 88 (2): 553–8. doi:10.1210/jc.2002-021251. PMID 12574179.
- ↑ 2.0 2.1 Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC; et al. (1995). “Plasma metanephrines in the diagnosis of pheochromocytoma”. Ann Intern Med. 123 (2): 101–9. doi:10.7326/0003-4819-123-2-199507150-00004. PMID 7778821.
- ↑ Pattarino F, Bouloux PM (1996). “The diagnosis of malignancy in phaeochromocytoma”. Clin Endocrinol (Oxf). 44 (2): 239–41. doi:10.1046/j.1365-2265.1996.657475.x. PMID 8849581.
- ↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). “Biochemical diagnosis of pheochromocytoma: which test is best?”. JAMA. 287 (11): 1427–34. PMID 11903030.
- ↑ Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER; et al. (2006). “Phaeochromocytoma, new genes and screening strategies”. Clin Endocrinol (Oxf). 65 (6): 699–705. doi:10.1111/j.1365-2265.2006.02714.x. PMID 17121518.
- ↑ Kudva YC, Sawka AM, Young WF (2003). “Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience”. J Clin Endocrinol Metab. 88 (10): 4533–9. doi:10.1210/jc.2003-030720. PMID 14557417.
- ↑ Young WF, Maddox DE (1995). “Spells: in search of a cause”. Mayo Clin Proc. 70 (8): 757–65. PMID 7630214.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
